Market News AIOpen the app

PRQR stock news · ProQR Therapeutics

Stories about ProQR Therapeutics (PRQR) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for PRQR

Follow ProQR Therapeutics (PRQR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PRQR
Free on the App Store and Google Play, or on the web.
  1. Nov 16, 2026, 3:03 AM ET · Opinion

    BofA Securities analyst Alec Stranahan lowered the price target for ProQR Therapeutics from $8 to $7.

    Neutral

    BofA kept its Buy rating on ProQR but cut its price target from $8 to $7. Those mixed comments do not report a change in ProQR's business.